bioportfolio
Drug formulators should consider the physical properties of their products during pharmaceutical drug development. The physical properties of a solid drug substance are highly dependent on the solid form. It is critical to understand the solid form landscape and select the optimum solid form for drug performance, stability and manufacturability as early in the development process as possible. Join this free webinar to learn about different solid forms (polymorph and salt) and different technologies to achieve these forms
Watch Now
Peptide and oligonucleotide drugs are versatile therapeutics with a growing range of applications and many similarities in terms and of manufacturing and regulation.
Watch Now
Charles River
What does the future of your drug discovery program look like? Many industry leaders are finding themselves in uncharted waters: the science is more sophisticated than ever, producing paradigm-altering treatments. But, historically high R&D costs and low success rates has emphasized the need to identify drugs focused on translationally-relevant targets in the most cost and time efficient way.
Watch Now
Charles River
Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.
Watch Now